Uncategorized
pSivida enters partnership for sustained-release glaucoma drug development
pSivida has signed an agreement with an unnamed global pharmaceutical company to develop two glaucoma drugs using its proprietary sustained-release technology, according to a company press release.The partnership includes $750,000 in upfront payments to pSivida for initial development and $200,000 in potential additional payments, the release said.